Anteris Technologies Global Corp. (AVR) has one especially busy relationship: LeMaitre Vascular (LMAT) appears in four different seats around the business. It is disclosed as a supplier, customer, distributor and transition-services partner. The corporate org chart is doing more folding than unfolding.
The supplier relationship comes from a transition arrangement tied to Anteris’s regenerative-tissue products. In a filing dated Nov. 12, 2025, Anteris says:
"Concurrent with such sale, we entered into a Transition Services Agreement pursuant to which we manufactured and sold CardioCel™ and VascuCel™ products to LeMaitre."
Anteris / SEC filing / Nov. 12, 2025
That sentence describes Anteris manufacturing and selling the products to LeMaitre, but the relationship list identifies LeMaitre as a supplier for Anteris as well. The same counterparty sits inside the product handoff from more than one direction.
Anteris also names LeMaitre as a customer in its product-cost disclosure:
"Cost of products sold reflects the manufacturing cost from the sale of regenerative tissue products to 4C and to LeMaitre."
Anteris / SEC filing / Aug. 11, 2025
The plain-English version: LeMaitre is not merely a name in a commercial agreement. Anteris says it sells regenerative-tissue products to the company, alongside 4C Medical Technologies.
The distributor role is even more explicit. In a May 12, 2026 filing, Anteris says:
"Such sales have historically been made principally to 4C Medical Technologies, Inc. (“4C”) and, in prior periods, to LeMaitre Vascular, Inc. (“LeMaitre”), a distributor of medical products."
Anteris / SEC filing / May 12, 2026
That disclosure places LeMaitre in the route to market, although Anteris describes those sales as occurring in prior periods. A separate February 2026 filing again describes the transition-services agreement and the sale of CardioCel and VascuCel products to LeMaitre. One relationship, several labels, and a product handoff that has changed over time.
LeMaitre also shows up in Anteris’s cash history. Anteris attributes $1.4 million of deferred proceeds to LeMaitre, relating to the 2019 sale of distribution rights. And LeMaitre’s own filing, dated May 6, 2026, names Anteris as an investee. The tie therefore runs through distribution rights and ownership language, not just product sales.
Medtronic (MDT) occupies a different cluster of seats. Anteris disclosed a stock purchase agreement under which Medtronic agreed to buy 15,652,173 shares:
"On January 20, 2026, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Medtronic, pursuant to which the Company agreed to issue and sell to Medtronic 15,652,173 shares of Common Stock…"
Anteris / SEC filing / Feb. 26, 2026
Anteris also disclosed restrictions on Medtronic’s transfers through Jan. 22, 2029, including prohibitions on transfers to activist investors or certain other parties. The same filing then supplies the unusual footnote: Medtronic directly competes with Anteris and may hold interests in other businesses that compete with it.
Finally, Artivion (AORT) calls Anteris a competitor in its own May 8, 2026 filing. Anteris’s disclosed map is therefore concentrated around two public companies: LeMaitre touches the product and distribution chain from multiple angles, while Medtronic combines investment, transfer restrictions and competition. The filings do not require a cleaner diagram than that.